Sigal Kaplan, PhD, BPharm
Teva Pharmaceutical Industries Ltd., Netanya, Israel
Original Research
Outcomes and Practice Patterns of LAI Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the US
March 2, 2026
Long-acting injectable antipsychotics, especially second-generation formulations, are associated with reduced rehospitalization in bipolar I disorder compared to oral antipsychotics.
